Results 131 to 140 of about 626,377 (227)

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol [PDF]

, 2013
Steve Poirier,1,2 Gaétan Mayer1–31Laboratory of Molecular Cell Biology, Montreal Heart Institute, Montréal, QC, Canada; 2Départements de Pharmacologie, 3Médecine, Faculté de Médecine, Université de ...
Poirier S, Mayer G
core  

Mitochondrial Fusion and Fission in Age‐Related Cardio‐Cerebral Diseases: Mechanisms and Interventions

Aging Cell, Volume 25, Issue 10, October 2026.
Mitochondrial fission‐fusion imbalance contributes to age‐related cardio‐cerebral diseases like Alzheimer's disease, Parkinson's disease, Cerebral Infarction, Arteriosclerosis, Myocardial Infarction, Cardiac valve disease, Hypertension, and Cardiomyopathy. This review summarizes its regulatory mechanisms and interventions.
Yuyao Yin, Zijian Li
wiley   +1 more source

PCSK9 inhibitors in the current management of atherosclerosis

Archivos de Cardiología de México, 2017
The history of proprotein convertase subtilisin/kexin type 9 (PCSK9) in medical science is fascinating and the evolution of knowledge of its function has resulted in new medications of major importance for the cardiovascular (CV) patient. PCSK9 functions as a negative control or feedback for the cell surface receptors for low-density lipoprotein ...
openaire   +2 more sources

Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9346-9355, October 2026.
ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg, Simon Maria Kienle, Asger Wretlind, Viktor Rotbain Curovic, Martin Bæk Blond, Hiddo J. L. Heerspink, Tine Willum Hansen, Frederik Persson, Karolina Sulek, Cristina Legido‐Quigley, Peter Rossing   +10 more
wiley   +1 more source

Cholesterol and stroke: role of PCSK9 inhibitors

, 2019
Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the modulation of plasma levels of low density lipoprotein cholesterol (LDLC).
M.A. Rico-Corral, M.C. Fernández-Moreno, L. Castilla-Guerra   +2 more
core   +1 more source

Cost-Effectiveness Analysis of PCSK9 Inhibitors in Norway

, 2016
Title: Cost-Effectiveness Analysis of PCSK9 Inhibitors in Norway Introduction & Background: Cardiovascular disease (CVD) is the biggest cause of premature death and loss of quality of life in the developed world.
Korman, Max Joseph
core  

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases

Cardiovascular disease (CVD) and ischemic stroke (IS) are the primary causes of mortality worldwide. Hypercholesterolemia has been recognized as an independent risk factor for CVD and IS.
Zhenzhen Li, Yiting Zhang, Yukai Liu, Meng Wang, Junshan Zhou, Qiwen Deng, Yeqiong Xu, Lin Zhu, Huiling Sun, Shuo Li, Teng Jiang   +10 more
core   +1 more source

PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option

, 2018
Elevated low-density lipoprotein cholesterol (LDL-C) plays a major role in the development of atherosclerotic cardiovascular disease. Statins are the first-line treatment to lower LDL-C in patients with hypercholesterolemia; however, some high ...
Gregory S. Pokrywka (4885189)
core   +1 more source

Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis

BMC Cardiovascular Disorders
Background Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite statin therapy, many patients fail to
Guoying Kao, Chuan Chen, Ying Zhang, Yi Xu, Gang Xu   +4 more
doaj   +1 more source

Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis

International Journal for Equity in Health
Background PCSK9 inhibitors are a novel class of lipid-lowering drugs that have demonstrated favorable efficacy and safety. Evolocumab and alirocumab have been added to China’s National Reimbursement Drug List through the National Drug Price Negotiation (
Lingli Zhang, Xiaoye Wang, Hongting Yao, Baolong Ding, Xingyuan Gao, Xin Li   +5 more
doaj   +1 more source